Farshid Dayyani

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 45

Top Topics

Antiplatelet Therapy

Metastatic Renal Cell Carcinoma

Circulating Tumor

Top Venues

JCO precision oncology

Diseases (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

John Yeakel, Steven N Seyedin, Garrett K Harada, Garo Hagopian, Sharmeen Mahmood, Rebecca Bennett, Jeremy P Harris, Elliot M Abbott, Sydney Lindner, Farshid Dayyani, Varun Sehgal, Jeffrey V Kuo, Nadine Abi-Jaoudeh
The Impact of Local Control on Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Cancer: A Retrospective Analysis. Cancers 16 (13) (2024)
Aditya Mahadevan, Armon Azizi, Cyrus Dastur, Sara Stern-Nezer, Jeffry Nahmias, Farshid Dayyani
Characterization of patients requiring inpatient hospital ethics consults- A single center study. PloS one 19 (4) (2024)
John Yeakel, Steven N Seyedin, Garrett K Harada, Garo Hagopian, Sharmeen Mahmood, Rebecca Bennett, Jeremy P Harris, Elliot M Abbott, Sydney Lindner, Farshid Dayyani, Varun Sehgal, Jeffrey V Kuo, Nadine Abi-Jaoudeh
The Impact of Local Control on Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Cancer: A Retrospective Analysis. Cancers 16 (13) (2024)
Amy Y Li, Shaina Sedighim, Fatemeh Tajik, Aaqil M Khan, Vinodh K Radhakrishnan, Farshid Dayyani, Maheswari Senthil
Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease. Journal of gastrointestinal cancer 55 (2) (2024)
Gregory P Botta, Maen Abdelrahim, Ronald L Drengler, Vasily N Aushev, Abdullah Esmail, George Laliotis, Chris M Brewer, Giby V George, Steven M Abbate, Sreenivasa R Chandana, Mohamedtaki A Tejani, Midhun Malla, Dhruv Bansal, Samuel Rivero-Hinojosa, Erik Spickard, Nicole McCormick, Michael Cecchini, Jill Lacy, Naomi Fei, Pashtoon Murtaza Kasi, Anup Kasi, Farshid Dayyani, Diana L Hanna, Shruti Sharma, Meenakshi Malhotra, Alexey Aleshin, Minetta C Liu, Adham Jurdi
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. The oncologist (2024)
Farshid Dayyani, Joseph Chao, Fa-Chyi Lee, Thomas H Taylor, Kristen Neumann, May T Cho
A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors. The oncologist 29 (8) (2024)
Aditya Mahadevan, Armon Azizi, Cyrus Dastur, Sara Stern-Nezer, Jeffry Nahmias, Farshid Dayyani
Characterization of patients requiring inpatient hospital ethics consults- A single center study. PloS one 19 (4) (2024)
Aditya Mahadevan, Armon Azizi, Cyrus Dastur, Sara Stern-Nezer, Jeffry Nahmias, Farshid Dayyani
Characterization of patients requiring inpatient hospital ethics consults- A single center study. PloS one 19 (4) (2024)
Gregory P Botta, Maen Abdelrahim, Ronald L Drengler, Vasily N Aushev, Abdullah Esmail, George Laliotis, Chris M Brewer, Giby V George, Steven M Abbate, Sreenivasa R Chandana, Mohamedtaki A Tejani, Midhun Malla, Dhruv Bansal, Samuel Rivero-Hinojosa, Erik Spickard, Nicole McCormick, Michael Cecchini, Jill Lacy, Naomi Fei, Pashtoon Murtaza Kasi, Anup Kasi, Farshid Dayyani, Diana L Hanna, Shruti Sharma, Meenakshi Malhotra, Alexey Aleshin, Minetta C Liu, Adham Jurdi
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. The oncologist (2024)
Aditya Mahadevan, Armon Azizi, Farshid Dayyani
Beginning at the End? Rethinking the Timing of Enrollment Into Early Phase Clinical Trials. JCO oncology practice (2024)
Amy Y Li, Shaina Sedighim, Fatemeh Tajik, Aaqil M Khan, Vinodh K Radhakrishnan, Farshid Dayyani, Maheswari Senthil
Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease. Journal of gastrointestinal cancer 55 (2) (2024)
Farshid Dayyani, Joseph Chao, Fa-Chyi Lee, Thomas H Taylor, Kristen Neumann, May T Cho
A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors. The oncologist (2024)
Farshid Dayyani, Joseph Chao, Fa-Chyi Lee, Thomas H Taylor, Kristen Neumann, May T Cho
A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors. The oncologist 29 (8) (2024)
Amy Y Li, Shaina Sedighim, Fatemeh Tajik, Aaqil M Khan, Vinodh K Radhakrishnan, Farshid Dayyani, Maheswari Senthil
Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease. Journal of gastrointestinal cancer 55 (2) (2024)
Amy Y Li, Shaina Sedighim, Fatemeh Tajik, Aaqil M Khan, Vinodh K Radhakrishnan, Farshid Dayyani, Maheswari Senthil
Regional Therapy Approaches for Gastric Cancer with Limited Peritoneal Disease. Journal of gastrointestinal cancer (2024)
Jingjing Yu, Arsha Ostowari, Amber Gonda, Kiarash Mashayekhi, Farshid Dayyani, Christopher C W Hughes, Maheswari Senthil
Exosomes as a Source of Biomarkers for Gastrointestinal Cancers. Cancers 15 (4) (2023)
Dalia Kaakour, Garrett Ward, Maheswari Senthil, Farshid Dayyani
Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix. Diseases (Basel, Switzerland) 11 (2) (2023)
Farshid Dayyani, Whayoung Lee, Roozbeh Houshyar, Pauline Fontaine
Rapid and Deep Response to Lorlatinib in Pancreatic High-Grade Neuroendocrine Carcinoma With a Treatment Emergent Novel KANK1-ALK Fusion. JCO precision oncology 7 (2023)
Dalia Kaakour, Garrett Ward, Maheswari Senthil, Farshid Dayyani
Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix. Diseases (Basel, Switzerland) 11 (2) (2023)
Farshid Dayyani, Whayoung Lee, Roozbeh Houshyar, Pauline Fontaine
Rapid and Deep Response to Lorlatinib in Pancreatic High-Grade Neuroendocrine Carcinoma With a Treatment Emergent Novel KANK1-ALK Fusion. JCO precision oncology 7 (2023)
Jingjing Yu, Arsha Ostowari, Amber Gonda, Kiarash Mashayekhi, Farshid Dayyani, Christopher C W Hughes, Maheswari Senthil
Exosomes as a Source of Biomarkers for Gastrointestinal Cancers. Cancers 15 (4) (2023)
Jingjing Yu, Arsha Ostowari, Amber Gonda, Kiarash Mashayekhi, Farshid Dayyani, Christopher C W Hughes, Maheswari Senthil
Exosomes as a Source of Biomarkers for Gastrointestinal Cancers. Cancers 15 (4) (2023)
Dalia Kaakour, Garrett Ward, Maheswari Senthil, Farshid Dayyani
Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix. Diseases (Basel, Switzerland) 11 (2) (2023)
Kenneth N Huynh, Sriram Rao, Bradley Roth, Theodore Bryan, Dayantha M Fernando, Farshid Dayyani, David Imagawa, Nadine Abi-Jaoudeh
Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma. Cancers 15 (10) (2023)
Dalia Kaakour, Garrett Ward, Maheswari Senthil, Farshid Dayyani
Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix. Diseases (Basel, Switzerland) 11 (2) (2023)
Farshid Dayyani, Whayoung Lee, Roozbeh Houshyar, Pauline Fontaine
Rapid and Deep Response to Lorlatinib in Pancreatic High-Grade Neuroendocrine Carcinoma With a Treatment Emergent Novel KANK1-ALK Fusion. JCO precision oncology 7 (2023)
Sharmeen Mahmood, Daneng Li, Arielle Lee, Julie Rowe, Muhammed Beg, Vijay Kasturi, Renuka Iyer, Thomas Abrams, Farshid Dayyani
A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE). Future oncology (London, England) (2023)
Dalia Kaakour, Garrett Ward, Maheswari Senthil, Farshid Dayyani
Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix. Diseases (Basel, Switzerland) 11 (2) (2023)
Naomie Devico Marciano, Gianna Kroening, Farshid Dayyani, Jason A Zell, Fa-Chyi Lee, May Cho, Jennifer Goldstein Valerin
BRCA -Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. Cancers 14 (10) (2022)
Farshid Dayyani, Shumei Kato, Razelle Kurzrock
Hyperprogression in Gastric Cancer: Is MDM2 Amplification the Dark Horse? JCO precision oncology 5 (2022)
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, Joseph Chao, Farshid Dayyani, Diana Hanna, Gregory P Botta, Daniel V T Catenacci, Steven B Maron, Shifra Krinshpun, Shruti Sharma, Giby V George, Meenakshi Malhotra, Adham Jurdi, Solomon Moshkevich, Alexey Aleshin, Pashtoon Murtaza Kasi, Samuel J Klempner
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO precision oncology 6 (2022)
Farshid Dayyani, Kit Tam, Edward J Kim, Samuel Ejadi, Jennifer Valerin, Thomas H Taylor, May T Cho
A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. Medical oncology (Northwood, London, England) 39 (5) (2022)
Andrew X Zhu, Farshid Dayyani, Chia-Jui Yen, Zhenggang Ren, Yuxian Bai, Zhiqiang Meng, Hongming Pan, Paul Dillon, Shivani K Mhatre, Vincent E Gaillard, Sairy Hernandez, Robin Kate Kelley, Bruno Sangro
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (16) (2022)
Farshid Dayyani, Maheswari Senthil
Spontaneous Fluctuations of Tumor-Informed Circulating Tumor DNA at Low Levels. JCO precision oncology 6 (2022)
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, Joseph Chao, Farshid Dayyani, Diana Hanna, Gregory P Botta, Daniel V T Catenacci, Steven B Maron, Shifra Krinshpun, Shruti Sharma, Giby V George, Meenakshi Malhotra, Adham Jurdi, Solomon Moshkevich, Alexey Aleshin, Pashtoon Murtaza Kasi, Samuel J Klempner
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO precision oncology 6 (2022)
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, Joseph Chao, Farshid Dayyani, Diana Hanna, Gregory P Botta, Daniel V T Catenacci, Steven B Maron, Shifra Krinshpun, Shruti Sharma, Giby V George, Meenakshi Malhotra, Adham Jurdi, Solomon Moshkevich, Alexey Aleshin, Pashtoon Murtaza Kasi, Samuel J Klempner
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO precision oncology 6 (2022)
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, Joseph Chao, Farshid Dayyani, Diana Hanna, Gregory P Botta, Daniel V T Catenacci, Steven B Maron, Shifra Krinshpun, Shruti Sharma, Giby V George, Meenakshi Malhotra, Adham Jurdi, Solomon Moshkevich, Alexey Aleshin, Pashtoon Murtaza Kasi, Samuel J Klempner
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO precision oncology 6 (2022)
Dalia Kaakour, Garrett Ward, Farshid Dayyani
Early Adoption of Checkpoint Inhibitors in Patients with Metastatic Gastric Adenocarcinoma-A Case Series of Non-Operative Long-Term Survivors. Diseases (Basel, Switzerland) 10 (2) (2022)
Brandon M Huffman, Vasily N Aushev, Griffin L Budde, Joseph Chao, Farshid Dayyani, Diana Hanna, Gregory P Botta, Daniel V T Catenacci, Steven B Maron, Shifra Krinshpun, Shruti Sharma, Giby V George, Meenakshi Malhotra, Adham Jurdi, Solomon Moshkevich, Alexey Aleshin, Pashtoon Murtaza Kasi, Samuel J Klempner
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. JCO precision oncology 6 (2022)
Farshid Dayyani, Brian R Smith, Ninh T Nguyen, Shaun Daly, Marcelo W Hinojosa, Steven N Seyedin, Jeffrey Kuo, Jason B Samarasena, John G Lee, Thomas H Taylor, May T Cho, Maheswari Senthil
A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC). Future oncology (London, England) 18 (21) (2022)
Andrew X Zhu, Alexander R Abbas, Marina Ruiz de Galarreta, Yinghui Guan, Shan Lu, Hartmut Koeppen, Wenjun Zhang, Chih-Hung Hsu, Aiwu Ruth He, Baek-Yeol Ryoo, Thomas Yau, Ahmed O Kaseb, Adam M Burgoyne, Farshid Dayyani, Jessica Spahn, Wendy Verret, Richard S Finn, Han Chong Toh, Amaia Lujambio, Yulei Wang
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nature medicine 28 (8) (2022)
May T Cho, Sepideh Gholami, Dorina Gui, Sooraj L Tejaswi, Ghaneh Fananapazir, Nadine Abi-Jaoudeh, Zeljka Jutric, Jason B Samarasena, Xiaodong Li, Jennifer B Valerin, Jacob Mercer, Farshid Dayyani
Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach. Cancers 14 (2) (2022)
Nadine Abi-Jaoudeh, Farshid Dayyani, Pei Jer Chen, Dayantha M Fernando, Nicholas Fidelman, Hanna Javan, Po-Chin Liang, Jen-I Hwang
Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma. Journal of hepatocellular carcinoma 8 (2021)
Samuel J Klempner, Russell Madison, Vivek Pujara, Jeffrey S Ross, Vincent A Miller, Siraj M Ali, Alexa B Schrock, Seung Tae Kim, Steven B Maron, Farshid Dayyani, Daniel V T Catenacci, Jeeyun Lee, Joseph Chao
FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. The oncologist 24 (11) (2019)
Stefan Holdenrieder, Lance Pagliaro, David Morgenstern, Farshid Dayyani
Clinically Meaningful Use of Blood Tumor Markers in Oncology. BioMed research international 2016 (2016)